{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:25:07Z","timestamp":1793053507090,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.xkme.2026.101297","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:27:39Z","timestamp":1771028859000},"page":"101297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["SGLT2 Inhibitors, Muscle Loss, and Creatinine-Based Estimated GFR: An Integrative Conceptual Review of Renoprotection"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1886-4451","authenticated-orcid":false,"given":"Dion","family":"Groothof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naser B.N.","family":"Shehab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9370-6832","authenticated-orcid":false,"given":"Nicole S.","family":"Erler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinold O.B.","family":"Gans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan J.L.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10397","key":"10.1016\/j.xkme.2026.101297_bib1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","year":"2023","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.xkme.2026.101297_bib2","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.xkme.2026.101297_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.xkme.2026.101297_bib4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41581-020-00350-x","article-title":"Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation","volume":"17","author":"Marton","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1016\/j.xkme.2026.101297_bib5","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3390\/jcm9051603","article-title":"Sodium-glucose cotransporter 2 inhibitors and kidney outcomes: true renoprotection, loss of muscle mass or both?","volume":"9","author":"Post","year":"2020","journal-title":"J Clin Med"},{"issue":"10191","key":"10.1016\/j.xkme.2026.101297_bib6","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1016\/S0140-6736(19)31138-9","article-title":"Sarcopenia","volume":"393","author":"Cruz-Jentoft","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.xkme.2026.101297_bib7","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1152\/physrev.2000.80.3.1107","article-title":"Creatine and Creatinine Metabolism","volume":"80","author":"Wyss","year":"2000","journal-title":"Physiol Rev"},{"issue":"4-suppl","key":"10.1016\/j.xkme.2026.101297_bib8","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.xkme.2026.101297_bib9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the national kidney foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.xkme.2026.101297_bib10","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/jcsm.12969","article-title":"Muscle Mass and Estimates of Renal Function: A Longitudinal Cohort Study","volume":"13","author":"Groothof","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"10","key":"10.1016\/j.xkme.2026.101297_bib11","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of type 2 diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.xkme.2026.101297_bib12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"10.1016\/j.xkme.2026.101297_bib13","doi-asserted-by":"crossref","first-page":"771","DOI":"10.34067\/KID.0000000000000425","article-title":"SGLT2 inhibitors and kidney protection: mechanisms beyond tubuloglomerular feedback","volume":"5","author":"Upadhyay","year":"2024","journal-title":"Kidney360"},{"issue":"2","key":"10.1016\/j.xkme.2026.101297_bib14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2337\/dc20-1983","article-title":"Gluconeogenesis, but not glycogenolysis, contributes to the increase in endogenous glucose production by SGLT-2 inhibition","volume":"44","author":"Wolf","year":"2021","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.xkme.2026.101297_bib15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(20)30382-X","article-title":"Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial","volume":"9","author":"Jensen","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.xkme.2026.101297_bib16","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","article-title":"Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Jongs","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101297_bib17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ki.2013.490","article-title":"Microalbuminuria: target for renoprotective therapy PRO","volume":"86","author":"Roscioni","year":"2014","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.xkme.2026.101297_bib18","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1001\/archinte.1994.00420110021004","article-title":"Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease","volume":"154","author":"ter Wee","year":"1994","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.xkme.2026.101297_bib19","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJM199503093321006","article-title":"Hypoxia of the renal medull--its implications for disease","volume":"332","author":"Brezis","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2026.101297_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103942","article-title":"Hypoxia and chronic kidney disease","volume":"77","author":"Wang","year":"2022","journal-title":"EBioMedicine"},{"issue":"21","key":"10.1016\/j.xkme.2026.101297_bib21","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of Ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.xkme.2026.101297_bib22","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.34067\/KID.0000000617","article-title":"Adapting clinical and research practice to global warming: physiology-based interim recommendations for managing hypertonicity risk during extreme heat","volume":"5","author":"Groothof","year":"2024","journal-title":"Kidney360"},{"issue":"9","key":"10.1016\/j.xkme.2026.101297_bib23","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/ndt\/gfae032","article-title":"How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial","volume":"39","author":"Wanner","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.xkme.2026.101297_bib24","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.xkme.2026.101297_bib25","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.2337\/dc24-2244","article-title":"Exploring kidney oxygenation responses to dapagliflozin, exenatide, and their combination in patients with type 2 diabetes and chronic kidney disease: observations from a prespecified pilot study of a randomized crossover trial","volume":"48","author":"Apperloo","year":"2025","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.xkme.2026.101297_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-24280-9","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis","volume":"12","author":"Manosroi","year":"2022","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.xkme.2026.101297_bib27","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00125-023-05876-w","article-title":"Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial","volume":"66","author":"Gullaksen","year":"2023","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.xkme.2026.101297_bib28","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/ndt\/gfaf046","article-title":"Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease","volume":"40","author":"Bakker","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.xkme.2026.101297_bib29","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1111\/dom.14779","article-title":"Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial","volume":"24","author":"Sen","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.xkme.2026.101297_bib30","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00125-021-05512-5","article-title":"Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial","volume":"64","author":"Sen","year":"2021","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.xkme.2026.101297_bib31","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.xkme.2026.101297_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14659","article-title":"Overestimation of glomerular filtration rate calculated from creatinine as compared with cystatin C in patients with type 2 diabetes receiving sodium-glucose cotransportor 2 inhibitors","volume":"39","author":"Choosongsang","year":"2022","journal-title":"Diabet Med"},{"issue":"4","key":"10.1016\/j.xkme.2026.101297_bib33","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/jcsm.13511","article-title":"Creatinine, cystatin C, muscle mass, and mortality: findings from a primary and replication population-based cohort","volume":"15","author":"Groothof","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.xkme.2026.101297_bib34","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","article-title":"A formula to estimate the approximate surface area if height and weight be known","volume":"17","author":"Du Bois","year":"1916","journal-title":"Arch Intern Med (Chic)"},{"issue":"9","key":"10.1016\/j.xkme.2026.101297_bib35","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"19","key":"10.1016\/j.xkme.2026.101297_bib36","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.xkme.2026.101297_bib37","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1681\/ASN.2021070988","article-title":"A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease","volume":"32","author":"Delgado","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.xkme.2026.101297_bib38","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/ajcn\/63.6.863","article-title":"Total-body skeletal muscle mass: evaluation of 24-h urinary creatinine excretion by computerized axial tomography","volume":"63","author":"Wang","year":"1996","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"10.1016\/j.xkme.2026.101297_bib39","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/ajcn\/37.3.478","article-title":"Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method","volume":"37","author":"Heymsfield","year":"1983","journal-title":"Am J Clin Nutr"},{"issue":"7","key":"10.1016\/j.xkme.2026.101297_bib40","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/ndt\/gfr181","article-title":"When to initiate dialysis--is early start always better?","volume":"26","author":"Liberek","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1016\/j.xkme.2026.101297_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae335","article-title":"Push toward pre-emptive kidney transplantation - for sure?","volume":"17","author":"Cseprekal","year":"2024","journal-title":"Clin Kidney J"},{"issue":"24","key":"10.1016\/j.xkme.2026.101297_bib42","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.xkme.2026.101297_bib43","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.xkme.2026.101297_bib44","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1111\/dom.16478","article-title":"Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and\/or chronic kidney disease: the DAPASALT trial","volume":"27","author":"Beernink","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.xkme.2026.101297_bib45","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S2213-8587(25)00222-0","article-title":"Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis","volume":"13","author":"Herrington","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"10.1016\/j.xkme.2026.101297_bib46","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","article-title":"Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant","volume":"341","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.xkme.2026.101297_bib47","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/ki.2013.316","article-title":"Increased mortality early after dialysis initiation: a universal phenomenon","volume":"85","author":"Noordzij","year":"2014","journal-title":"Kidney Int"},{"issue":"13","key":"10.1016\/j.xkme.2026.101297_bib48","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease","volume":"330","author":"Klahr","year":"1994","journal-title":"N Engl J Med"},{"issue":"9069","key":"10.1016\/j.xkme.2026.101297_bib49","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.xkme.2026.101297_bib50","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1017\/S0029665115000129","article-title":"Skeletal muscle mass and quality: Evolution of modern measurement concepts in the context of sarcopenia","volume":"74","author":"Heymsfield","year":"2015","journal-title":"Proc Nutr Soc"},{"issue":"1","key":"10.1016\/j.xkme.2026.101297_bib51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"issue":"2","key":"10.1016\/j.xkme.2026.101297_bib52","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/jcsm.12686","article-title":"Muscle mass versus body mass index as predictor of adverse outcome","volume":"12","author":"Groothof","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526000580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526000580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:49:49Z","timestamp":1777312189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526000580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2590059526000580"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101297","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 Inhibitors, Muscle Loss, and Creatinine-Based Estimated GFR: An Integrative Conceptual Review of Renoprotection","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101297","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101297"}}